Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kohler, H.P.
Right arrow Articles by Grant, P.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohler, H.P.
Right arrow Articles by Grant, P.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 1999; 92: 67-72
© 1999 Association of Physicians

Mini-review

The role of factor XIIIVal34Leu in cardiovascular disease

H.P. Kohler and P.J. Grant

From the Unit of Molecular Vascular Medicine, Leeds General Infirmary, University of Leeds, Leeds, UK

Professor P.J. Grant, Unit of Molecular Vascular Medicine, G-Floor, Martin Wing, Leeds General Infirmary, Leeds LS1 3EX. e-mail: p.j.grant@leeds.ac.uk

Introduction

Blood coagulation factor XIII (also called fibrin-stabilizing factor1) plays an important role in clot stabilization by crosslinking fibrin chains.2 Factor XIII (FXIII) was discovered over 70 years ago by Barkan et al., who observed the insolubility of fibrin clots in the presence of calcium.3 Most studies on FXIII have been carried out in patients with FXIII deficiency which results in a serious bleeding diathesis, defective wound healing and a high risk of miscarriage in the deficient female.4,5 Most of these subjects show no plasma FXIII activity because of a complete absence of the A-subunit in plasma, platelets and monocytes.6 Little is known about the role of FXIII in vascular diseases. Although Kloczko et al. showed increased levels of FXIII A-subunit antigen in patients with obliterative atherosclerosis of the lower limbs and in patients with diabetic angiopathy, small patient numbers make the interpretation of these data difficult.7,8 . . . [Full Text of this Article]

Structure and function of FXIII

FXIII A-subunit gene

FXIIIVal34Leu

FXIII Val34Leu in patients with coronary heart disease

Prevalence of FXIIIVal34Leu in different ethnic groups

FXIIIVal34Leu in patients with cerebrovascular disease

FXIIIVal34Leu in venous thrombosis

FXIIIVal34Leu affects cross-linking activity

Conclusion

Acknowledgments

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. Kluft and J. Jespersen
Review: Diabetes as a procoagulant condition
The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 358 - 362.
[Abstract] [PDF]

Home page
 StrokeHome page
M. Weger, W. Renner, O. Stanger, O. Schmut, H. Deutschmann, T. C. Wascher, and A. Haas
Role of Factor XIII Val34Leu Polymorphism in Retinal Artery Occlusion
Stroke, December 1, 2001; 32(12): 2759 - 2761.
[Abstract] [Full Text] [PDF]